Bicara Therapeutics Inc. Common Stock (BCAX)

About BCAX

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

www.bicara.com/

Fundamentals

Market cap

$1.81B

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-2.77

Dividend yield

—

Beta

0.85

Avg. volume

—

Bicara Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.81BP/E —
  $10.3$30.99
• CMPS

  COMPASS Pathways Plc American Depository Shares

  $13.71

  ▼ 6.35%
  Market cap $1.83BP/E —
  $4.4$15.4
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.83BP/E —
  $7.02$47.66
• GENB

  Generate Biomedicines Inc. Common Stock

  $15.33

  ▼ 2.79%
  Market cap $1.78BP/E —
  $11$22.67
• SRPT

  Sarepta Therapeutics Inc. Common Stock (DE)

  $20.85

  ▼ 3.43%
  Market cap $1.77BP/E —
  $14.68$25.32
• SNDX

  Syndax Pharmaceuticals Inc. Common Stock

  $19.55

  ▼ 3.05%
  Market cap $1.76BP/E —
  $12.99$25.59
• ANIP

  ANI Pharmaceuticals Inc.

  $72.83

  ▼ 0.93%
  Market cap $1.86BP/E 18.72
  $70.15$99.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
  Benzinga · 8/19/2026
• Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
  Benzinga · 8/12/2026
• Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
  Benzinga · 8/12/2026
• Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39
  Benzinga · 8/12/2026
• Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
  SeekingAlpha · 8/12/2026
• Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
  Benzinga · 8/12/2026
• Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
  Benzinga · 8/12/2026
• Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23
  Benzinga · 8/12/2026

• Larson Jennifer · August 12, 2026 · Grant

  285.0K
• Ivan Hyep · August 10, 2026 · Option Exercise

  12.5K @ $3.79
• Ivan Hyep · August 10, 2026 · Sale

  12.5K @ $27.97
• Claire Mazumdar · August 10, 2026 · Option Exercise

  10.0K @ $3.79
• Claire Mazumdar · August 10, 2026 · Sale

  10.0K @ $27.98
• Ryan Cohlhepp · August 10, 2026 · Option Exercise

  18.8K @ $3.79
• Ryan Cohlhepp · August 10, 2026 · Sale

  18.8K @ $27.98
• Jeremy Bender · July 28, 2026 · Grant

  39.0K
• Oliger Christy J. · July 28, 2026 · Grant

  39.0K
• Claire Mazumdar · July 10, 2026 · Option Exercise

  10.0K @ $3.79
• Claire Mazumdar · July 10, 2026 · Sale

  28 @ $29.68
• Claire Mazumdar · July 10, 2026 · Sale

  10.0K @ $28.42
• Ryan Cohlhepp · July 9, 2026 · Sale

  536 @ $29
• Ryan Cohlhepp · July 8, 2026 · Option Exercise

  18.8K @ $3.79
• Ryan Cohlhepp · July 8, 2026 · Sale

  1.1K @ $30.35

Institutional Ownership

March 31, 2026

Total shares held

70.78M

Total value held

$1.22B

Institutional holders

142